Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study

Cesare Mazzaro, Francesca Zorat, Manuela Caizzi, Carlo Donada, Giampiero Di Gennaro, Luigino Dal Maso, Giorgio Carniello, Luigi Virgolini, Umberto Tirelli, Gabriele Pozzato

Research output: Contribution to journalArticle

Abstract

Background/Aims: The aim of this study is to verify the efficacy and safety of peg-interferon alfa-2b in combination with ribavirin for initial treatment of HCV-associated mixed cryoglobulinemia. Methods: Eighteen patients (7 women and 11 men) affected by mixed cryoglobulinemia were included in the study and treated with peg-interferon alfa-2b 1.0 μg/kg once a week plus ribavirin (1000 mg daily) for 48 weeks, regardless of the HCV genotype. Results: At the end of the treatment HCV-RNA became undetectable in 15 patients (83%) and most patients improved clinically. One subject suspended treatment at 13th week due to depression. A large fraction of the patients (8 cases: 44%) relapsed both virologically and clinically a few weeks after the end of therapy. At the end of follow-up, only eight patients (44%) obtained a sustained virological response. Conclusions: Peg-interferon alfa-2b in combination with ribavirin seems safe and useful for patients affected by mixed cryoglobulinemia, but not as effective as in patients with HCV-positive chronic hepatitis without cryoglobulinemia.

Original languageEnglish
Pages (from-to)632-638
Number of pages7
JournalJournal of Hepatology
Volume42
Issue number5
DOIs
Publication statusPublished - May 2005

Fingerprint

interferon alfa-2b
Cryoglobulinemia
Ribavirin
Hepacivirus
Therapeutics
Chronic Hepatitis

Keywords

  • Hepatitis C virus
  • Mixed cryoglobulinemia
  • Peg-interferon
  • Ribavirin
  • Vasculitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia : A pilot study. / Mazzaro, Cesare; Zorat, Francesca; Caizzi, Manuela; Donada, Carlo; Di Gennaro, Giampiero; Dal Maso, Luigino; Carniello, Giorgio; Virgolini, Luigi; Tirelli, Umberto; Pozzato, Gabriele.

In: Journal of Hepatology, Vol. 42, No. 5, 05.2005, p. 632-638.

Research output: Contribution to journalArticle

Mazzaro, C, Zorat, F, Caizzi, M, Donada, C, Di Gennaro, G, Dal Maso, L, Carniello, G, Virgolini, L, Tirelli, U & Pozzato, G 2005, 'Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study', Journal of Hepatology, vol. 42, no. 5, pp. 632-638. https://doi.org/10.1016/j.jhep.2004.10.031
Mazzaro, Cesare ; Zorat, Francesca ; Caizzi, Manuela ; Donada, Carlo ; Di Gennaro, Giampiero ; Dal Maso, Luigino ; Carniello, Giorgio ; Virgolini, Luigi ; Tirelli, Umberto ; Pozzato, Gabriele. / Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia : A pilot study. In: Journal of Hepatology. 2005 ; Vol. 42, No. 5. pp. 632-638.
@article{f1201416d92e49a78843ba72bd7ab35c,
title = "Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study",
abstract = "Background/Aims: The aim of this study is to verify the efficacy and safety of peg-interferon alfa-2b in combination with ribavirin for initial treatment of HCV-associated mixed cryoglobulinemia. Methods: Eighteen patients (7 women and 11 men) affected by mixed cryoglobulinemia were included in the study and treated with peg-interferon alfa-2b 1.0 μg/kg once a week plus ribavirin (1000 mg daily) for 48 weeks, regardless of the HCV genotype. Results: At the end of the treatment HCV-RNA became undetectable in 15 patients (83{\%}) and most patients improved clinically. One subject suspended treatment at 13th week due to depression. A large fraction of the patients (8 cases: 44{\%}) relapsed both virologically and clinically a few weeks after the end of therapy. At the end of follow-up, only eight patients (44{\%}) obtained a sustained virological response. Conclusions: Peg-interferon alfa-2b in combination with ribavirin seems safe and useful for patients affected by mixed cryoglobulinemia, but not as effective as in patients with HCV-positive chronic hepatitis without cryoglobulinemia.",
keywords = "Hepatitis C virus, Mixed cryoglobulinemia, Peg-interferon, Ribavirin, Vasculitis",
author = "Cesare Mazzaro and Francesca Zorat and Manuela Caizzi and Carlo Donada and {Di Gennaro}, Giampiero and {Dal Maso}, Luigino and Giorgio Carniello and Luigi Virgolini and Umberto Tirelli and Gabriele Pozzato",
year = "2005",
month = "5",
doi = "10.1016/j.jhep.2004.10.031",
language = "English",
volume = "42",
pages = "632--638",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia

T2 - A pilot study

AU - Mazzaro, Cesare

AU - Zorat, Francesca

AU - Caizzi, Manuela

AU - Donada, Carlo

AU - Di Gennaro, Giampiero

AU - Dal Maso, Luigino

AU - Carniello, Giorgio

AU - Virgolini, Luigi

AU - Tirelli, Umberto

AU - Pozzato, Gabriele

PY - 2005/5

Y1 - 2005/5

N2 - Background/Aims: The aim of this study is to verify the efficacy and safety of peg-interferon alfa-2b in combination with ribavirin for initial treatment of HCV-associated mixed cryoglobulinemia. Methods: Eighteen patients (7 women and 11 men) affected by mixed cryoglobulinemia were included in the study and treated with peg-interferon alfa-2b 1.0 μg/kg once a week plus ribavirin (1000 mg daily) for 48 weeks, regardless of the HCV genotype. Results: At the end of the treatment HCV-RNA became undetectable in 15 patients (83%) and most patients improved clinically. One subject suspended treatment at 13th week due to depression. A large fraction of the patients (8 cases: 44%) relapsed both virologically and clinically a few weeks after the end of therapy. At the end of follow-up, only eight patients (44%) obtained a sustained virological response. Conclusions: Peg-interferon alfa-2b in combination with ribavirin seems safe and useful for patients affected by mixed cryoglobulinemia, but not as effective as in patients with HCV-positive chronic hepatitis without cryoglobulinemia.

AB - Background/Aims: The aim of this study is to verify the efficacy and safety of peg-interferon alfa-2b in combination with ribavirin for initial treatment of HCV-associated mixed cryoglobulinemia. Methods: Eighteen patients (7 women and 11 men) affected by mixed cryoglobulinemia were included in the study and treated with peg-interferon alfa-2b 1.0 μg/kg once a week plus ribavirin (1000 mg daily) for 48 weeks, regardless of the HCV genotype. Results: At the end of the treatment HCV-RNA became undetectable in 15 patients (83%) and most patients improved clinically. One subject suspended treatment at 13th week due to depression. A large fraction of the patients (8 cases: 44%) relapsed both virologically and clinically a few weeks after the end of therapy. At the end of follow-up, only eight patients (44%) obtained a sustained virological response. Conclusions: Peg-interferon alfa-2b in combination with ribavirin seems safe and useful for patients affected by mixed cryoglobulinemia, but not as effective as in patients with HCV-positive chronic hepatitis without cryoglobulinemia.

KW - Hepatitis C virus

KW - Mixed cryoglobulinemia

KW - Peg-interferon

KW - Ribavirin

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=20144387752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144387752&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2004.10.031

DO - 10.1016/j.jhep.2004.10.031

M3 - Article

C2 - 15826710

AN - SCOPUS:20144387752

VL - 42

SP - 632

EP - 638

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -